DOI QR코드

DOI QR Code

Clinical Application of $^{18}F-FDG-PET/CT$ in Multiple Myeloma

다발골수종에서 $^{18}F-FDG-PET/CT$의 임상 적용

  • Kim, Jeong-A (Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
  • 김정아 (가톨릭대학교 의과대학 내과학교실)
  • Published : 2012.06.01

Abstract

Multiple myeloma (MM) is a plasma cell malignancy and is characterized by the presence of lytic bone disease causing severe bone pain, pathological fractures and spinal cord compression. Up to 80% of myeloma patients develop osteolytic lesions during the course of their disease. Appropriate use of imaging techniques is essential in the identification and characterization of the skeletal complications resulting from MM and in determination of the extent of intramedullary bone disease. Despite many weaknesses, conventional radiography still remains the standard for the staging procedure of newly diagnosed and relapsed myeloma patients. Magnetic resonance imaging (MRI) is recommended for MM patients with normal conventional radiography and for all patients with an apparently solitary plasmacytoma of bone. Urgent MRI is the diagnostic procedure of choice to assess suspected cord compression. Although Positron emission tomography/CT (PET/CT) is a useful method to assess the patient's response to the treatment and diagnose the extent of bone involvement and extramedullary disease in the patient, PET/CT is not recommended for routine use in myeloma patients. However, further studies are needed before the recommendation of using PET/CT as a standard tool in both diagnosis and follow-up of MM patients.

Keywords

References

  1. Kim HJ, Park JM, Cha JG, et al. $^{18}F$-FDG PET/CT in the clinical assessment of patients with multiple myeloma: a pilot study. Korean J Med 2012;82:689-695. https://doi.org/10.3904/kjm.2012.82.6.689
  2. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007;137:49-63. https://doi.org/10.1111/j.1365-2141.2007.06491.x
  3. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005;184:1199-1204. https://doi.org/10.2214/ajr.184.4.01841199
  4. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-1463.
  5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: multiple myeloma [Internet]. National Comprehensive Cancer Network, c2011 [cited 2011, 26th July]. Available from: http://www. nccn.org/professionals/physician_gls/pdf/ myeloma.pdf.
  6. Haznedar R, Akı SZ, Akdemir OU, et al. Value of 18Ffluorodeoxyglucose uptake in positron emission tomography/ computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 2011;38:1046-1053. https://doi.org/10.1007/s00259-011-1738-8
  7. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011;118:5989-5995. https://doi.org/10.1182/blood-2011-06-361386

Cited by

  1. Screening Tests for Early Diagnosis of Multiple Myeloma and Related Plasma Cell Disorders vol.96, pp.5, 2012, https://doi.org/10.3904/kjm.2021.96.5.371